Compare Stocks → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADMSNASDAQ:CLSNNASDAQ:MNPRNASDAQ:OTICNASDAQ:SESN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/ACLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsMNPRMonopar Therapeutics$0.66+5.1%$0.76$0.27▼$1.75$11.51M1.194.23 million shs28,137 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASESNSesen Bio$10.50$0.37▼$12.58$2.56B0.831.07 million shs93,330 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%CLSNImunon0.00%0.00%0.00%0.00%0.00%MNPRMonopar Therapeutics-4.49%-7.45%-14.78%+72.53%-44.96%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SESNSesen Bio0.00%0.00%0.00%0.00%0.00%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AN/AN/AN/AMNPRMonopar Therapeutics2.4476 of 5 stars3.55.00.00.00.61.70.6OTICOtonomyN/AN/AN/AN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas PharmaceuticalsN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AMNPRMonopar Therapeutics3.00Buy$2.00203.21% UpsideOTICOtonomyN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/ACurrent Analyst RatingsLatest CLSN, OTIC, SESN, ADMS, and MNPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2024MNPRMonopar TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$2.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49CLSNImunon$500K0.00N/AN/A$9.66 per share0.00MNPRMonopar TherapeuticsN/AN/AN/AN/A$0.38 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01SESNSesen Bio$40M0.00N/A3.39$0.78 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/ACLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/AMNPRMonopar Therapeutics-$8.40M-$0.61N/AN/AN/AN/A-115.79%-88.05%5/9/2024 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ASESNSesen Bio-$19.88M-$0.10N/AN/AN/AN/A6.70%5.41%N/ALatest CLSN, OTIC, SESN, ADMS, and MNPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023MNPRMonopar Therapeutics-$0.17-$0.12+$0.05-$0.12N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ASESNSesen BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17CLSNImunon0.136.526.52MNPRMonopar TherapeuticsN/A4.174.17OTICOtonomyN/A1.741.74SESNSesen BioN/A6.106.10OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%CLSNImunon12.97%MNPRMonopar Therapeutics1.83%OTICOtonomy41.23%SESNSesen Bio16.45%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%CLSNImunon4.66%MNPRMonopar Therapeutics41.60%OTICOtonomy1.09%SESNSesen Bio3.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableCLSNImunon277.10 million6.77 millionOptionableMNPRMonopar Therapeutics1117.45 million10.19 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableSESNSesen Bio35203.49 million196.98 millionOptionableCLSN, OTIC, SESN, ADMS, and MNPR HeadlinesSourceHeadlineTrey Mewesstartribune.com - April 10 at 12:53 AMDevin Haney: biography, record, fights and moreespn.com - December 9 at 5:50 PMTyson Fury: Biography, record, fights and moreespn.com - December 2 at 10:49 AMWhy the Tucker Carlson Biography Sales Are So Patheticthedailybeast.com - September 13 at 10:23 PMSesen Bio (NASDAQ: SESN)fool.com - August 4 at 6:23 PMJames McTeigue Biography & Moviestribute.ca - May 10 at 6:46 PMAfter revisions, Philadelphia-based Carisma Therapeutics poised to close merger with Sesen Biobizjournals.com - March 6 at 7:17 PMSesen Bio wins shareholder approval for Carisma mergermsn.com - March 2 at 1:30 PMSesen Bio Stockholders Approve Merger with Carisma Therapeuticsfinance.yahoo.com - March 2 at 1:30 PMSesen Bio Reports Fourth Quarter and Full-Year 2022 Financial Resultsfinance.yahoo.com - February 28 at 12:42 PMSHAREHOLDER ALERT: Weiss Law Reminds SESN, MLVF, VLON, and SHBI Shareholders About Its Ongoing Investigationsbenzinga.com - February 24 at 9:19 PMLeading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote "FOR" All Proposals to Approve Pending Merger With Carismafinance.yahoo.com - February 21 at 10:50 AMBML, One of Sesen Bio's Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsstockhouse.com - February 17 at 8:59 PMLeading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meetingbusinesswire.com - February 16 at 4:47 PMSesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Mergerfinance.yahoo.com - February 16 at 9:10 AMSesen Bio reaches deal with investor group, paving way for Carisma mergerendpts.com - February 15 at 2:11 PMLatest terms of Sesen Bio and Carisma merger appear to pass musterthepharmaletter.com - February 15 at 2:11 PM5 big dividend moves: Group 1 Automotive hikes by 20% | Pro Recapfinance.yahoo.com - February 15 at 9:11 AMBML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeuticsfinance.yahoo.com - February 15 at 9:11 AMSesen Bio, Carisma Therapeutics amend merger deal after reaching agreement with investor groupbizjournals.com - February 14 at 2:01 PMSesen gains 11% on amended terms for merger with Carismamsn.com - February 14 at 9:00 AMSesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Mergerfinance.yahoo.com - February 14 at 9:00 AMSesen Bio (NASDAQ:SESN) investors are sitting on a loss of 37% if they invested three years agofinance.yahoo.com - February 6 at 10:17 AMSesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Mergerfinance.yahoo.com - February 2 at 7:29 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioCanoo, Inc. Bites the Dust: Mullen Automotive Is a Better BetApril 2, 2024 9:15 AMView Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet3 Computer Vision Stocks for Long-Term Gains From AIApril 16, 2024 6:08 AMView 3 Computer Vision Stocks for Long-Term Gains From AICan Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?April 10, 2024 7:55 AMView Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?Intuitive Surgical Leads the Robotic Surgery MovementApril 22, 2024 6:10 AMView Intuitive Surgical Leads the Robotic Surgery MovementAll Headlines Company DescriptionsAdamas PharmaceuticalsNASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.Monopar TherapeuticsNASDAQ:MNPRMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.OtonomyNASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.Sesen BioNASDAQ:SESNSesen Bio, Inc. engages in designing, engineering, and developing targeted protein therapeutics. It offers Vicineum and Proxinium, which target tumor cell surface antigens that allow for rapid internalization into the targeted cancer cell and also have limited expression on normal cells. The company was founded by Reza Dana, K. Christopher Garcia, Gregory L. Verdine, Casey T. Weaver and K. Dane Wittrup on February 25, 2008 and is headquartered in Cambridge, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.